America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How does the selective targeting of mutated PCNA impact the side effects associated with cancer treatments?
**Interview with Dr. Linda Malkas, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope**
**Editor:** Thank you for joining us, Dr. Malkas. Your recent research on the AOH1996 molecule sounds groundbreaking. Can you explain how this drug works in targeting cancer cells?
**Dr. Malkas:** Thank you for having me. AOH1996 operates by selectively targeting a mutated form of PCNA, a protein that’s crucial for DNA replication and tumor growth. Think of PCNA as a large airline terminal—normally it helps with the flow of healthy cells. However, in cancer cells, it has unique mutations that allow us to target it specifically. Our drug acts like a blizzard disrupting the operations at this terminal, effectively halting the proliferation of cancer cells.
**Editor:** That’s an interesting analogy. What types of cancers have shown positive responses to AOH1996 in your studies?
**Dr. Malkas:** In our clinical research, we’ve seen promising results in treating various types of cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. It’s been effective across more than 70 cancer cell lines that we tested in the study published in ‘Cell Chemical Biology’.
**Editor:** These findings are certainly encouraging. What are the next steps in the development of AOH1996?
**Dr. Malkas:** The next critical step is to advance this research into clinical trials involving human patients. This will help us determine its safety and effectiveness in real-world applications and pave the way for potential treatment options.
**Editor:** Thank you, Dr. Malkas, for shedding light on this innovative research. We look forward to seeing how AOH1996 progresses in the fight against cancer.
**Dr. Malkas:** Thank you for the opportunity to share our work. Together, we hope to make significant strides in cancer treatment.